Uridine supplementation in the treatment of HIV lipoatrophy: Results of ACTG 5229

AIDS

Volumn 24, Issue 16, 2010, Pages 2507-2515

  McComsey, Grace A ^a   Walker, Ulrich A ^b   Budhathoki, Chakra B ^c   Su, Zhaohui ^c   Currier, Judith S ^d   Kosmiski, Lisa ^e   Naini, Linda G ^f   Charles, Stéphannie ^g   Medvik, Kathy ^a   Aberg, Judith A ^h  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f ACTG Operations Center   (United States)

^g Science and Technology Research Foundation   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Lipoatrophy; Lipodystrophy; Mitochondrial toxicity; Uridine

Indexed keywords

CD4 ANTIGEN; NUCLEOMAXX; PLACEBO; STAVUDINE; UNCLASSIFIED DRUG; URIDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERGLYCEMIA; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URIDINE SUPPLEMENTATION; WILCOXON SIGNED RANKS TEST;

ADULT; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MEDICATION ADHERENCE; PILOT PROJECTS; QUALITY OF LIFE; URIDINE; VIRAL LOAD;

EID: 78549238141     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ea9bc     Document Type: Article

References (21)

1. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-1338.
2. Walker UA, Bickel M, Lutke VolksbeckSI, Ketelsen UP, Schofer H, Setzer B, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor: associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002;29:117-121.
3. McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 2004;4:111-118.
4. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263-270.
5. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029-1036.
6. Moyle GJ, Sabin CA, CartledgeJ, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20:2043-2050.
7. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8:463-470.
8. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006;11:25-34.
9. Sutinen J, Walker UA, Sevastianova K, Klinker H, Hakkinen AM, Ristola M, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007; 12:97-105.
10. McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker uA. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2008;62:1031-1037.
11. van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM. Clinical and pharmacokinetic studies ofprolonged administration of high-dose uridine intended for rescue from 5-FU toxi- city. Cancer Treat Rep 1986; 70:745-750.
12. Leyva A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, et al. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 1984;44 (12 Pt 1):5928-5933.
13. Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 1988;32:997-1001;PMCID: 172332.
14. Calabresi P, Falcone A, St Clair MH, Wiemann MC, Chu SH, Darnowski JW. Benzylacyclouridine reverses azidothymidine- induced marrow suppression without impairment of antihu- man immunodeficiency virus activity. Blood 1990;76:2210-2215.
15. Koch EC, Schneider J, Weis R, Penning B, Walker UA. Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors. Antivir Ther 2003; 8:485-487.
16. Venhoff N, Zilly M, Lebrecht D, Schirmer D, Klinker H, Thoden J, et al. Uridine pharmacokinetics of mitocnol, a sugar cane extract. AIDS 2005;19:739-740.
17. Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007;45:72-79.
18. Setzer B, Lebrecht D, Walker UA. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 2008; 172:681-690; PMCID: 2258259.
19. Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1- infected individuals. J Acquir Immune Defic Syndr 2009;51:562-568.
20. Webster DR, Simmonds HA, Potter CF, Becroft DM. Purine and pyrimidine metabolism in hereditary oroticaciduria during a 15 year follow-up study. Adv Exp Med Biol 1979;122B:203-208.
21. Manis FR, Cohn LB, McBride-Chang C, Wolff JA, Kaufman FR. A longitudinal study of cognitive functioning in patients with classical galactosaemia, including a cohort treated with oral uridine. J Inherit Metab Dis 1997;20:549-555.